---
title: "Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Effects of other drugs"
description: "Formulary evidence on Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Effects of other drugs. Topics: Intravenous immunoglobulin: phase 1 Part C pharmacokinetic study and Immunoglobulin switch and prior complement or anti-CD20 therapy: CAPTIVATE. 2 evidence topics quoted from 2 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description/effects-of-other-drugs"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Effects of other drugs

<a id="heading-2.1.2.9.1"></a>

## 2.1.2.9.1 Effects of Other Drugs on Claseprubart

<a id="topic-2.1.2.9.1-1"></a>

### Intravenous immunoglobulin: phase 1 Part C pharmacokinetic study

> “Part A and Part B have already been registered and this registration of Part C will be evaluating DNTH103 PK following administration of human normal immunoglobulin (Ig)G. Part C will be open label and will not be placebo controlled.”
> “Single dose DNTH103, administered on Day 1 after administration of Privigen NZ solution for IV infusion on Days -8 and -7”
> “IV7, 0.5 g/kg of body weight per day for 2 consecutive days (total dose: 1 g/kg)”
> “Investigational Product: DNTH103 IV infusion, 1 week after Privigen NZ solution: • IV7, 10 mg/kg Investigational Product: DNTH103 SC injection, 1 week after Privigen NZ solution: • IV7, 600 mg”
> “To evaluate the pharmacokinetics (PK) of DNTH103 when administered IV following administration of IgG, as a single dose in healthy adult volunteers.”
> “Recruitment status Completed”

Source: [ANZCTR ACTRN12624000352505](https://anzctr.org.au/ACTRN12624000352505.aspx)

<a id="topic-2.1.2.9.1-2"></a>

### Immunoglobulin switch and prior complement or anti-CD20 therapy: CAPTIVATE

> “For patients on IV or SC Ig, the last dose for both must occur 1 week prior to Day 1 of Part A. Patients who received complement inhibitors or anti-CD20 treatments within the previous 6 months are not eligible.”

Source: [Allen et al. (2026d)](https://investor.dianthustx.com/static-files/61f3f3f9-f022-43e3-86d2-8534e2df4ac9)

## Related pages
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: References](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references.md)
